Literature DB >> 8040655

Depressive symptoms and the deficit syndrome of schizophrenia.

B Kirkpatrick1, R W Buchanan, A Breier, W T Carpenter.   

Abstract

One of the most influential ideas in schizophrenia research is that schizophrenia may be a syndrome with significant pathophysiological heterogeneity, rather than a single disease. Among patients with schizophrenia, presence or absence of the deficit syndrome has been suggested as a method for defining relatively homogeneous groups. The criteria for the deficit syndrome require the presence of negative symptoms that are judged primary to the illness, rather than to factors, such as depressive mood, that may resemble the negative symptoms of schizophrenia. To test one aspect of the validity of the primary/secondary judgment, we tested the relationship of depressive symptoms to the deficit/nondeficit categorization. Using independent clinician ratings, the depressive mood of deficit and nondeficit patients was compared at the time the categorization was made, and at an average follow-up of 2 1/2 years. Using patients' self ratings, deficit and nondeficit patients were compared at an average follow-up of 1 1/2 years. Deficit patients had significantly less severe depressive symptoms by clinicians' ratings both cross-sectionally and at follow-up, and less severe self-rated symptoms at follow-up. These differences were not due to confounding by age, race, sex, socioeconomic status, or chronicity. These results support the validity of the deficit/nondeficit categorization.

Entities:  

Mesh:

Year:  1994        PMID: 8040655     DOI: 10.1097/00005053-199408000-00005

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  13 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

Review 2.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

3.  Differences in glucose tolerance between deficit and nondeficit schizophrenia.

Authors:  Brian Kirkpatrick; Emilio Fernandez-Egea; Clemente Garcia-Rizo; Miguel Bernardo
Journal:  Schizophr Res       Date:  2008-11-28       Impact factor: 4.939

4.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

5.  An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia.

Authors:  Brian Kirkpatrick; Özlem Gürbüz Oflezer; Mehtap Delice Arslan; Gary Hack; Emilio Fernandez-Egea
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

6.  Posttraumatic stress disorder and negative symptoms of schizophrenia.

Authors:  Gregory P Strauss; Lisa A Duke; Sylvia A Ross; Daniel N Allen
Journal:  Schizophr Bull       Date:  2009-11-04       Impact factor: 9.306

7.  Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features.

Authors:  Hanan D Trotman; Brian Kirkpatrick; Michael T Compton
Journal:  Schizophr Res       Date:  2011-03       Impact factor: 4.939

8.  Will the Kraepelinian dichotomy survive DSM-V?

Authors:  Bernard A Fischer; William T Carpenter
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

9.  The impact of social content and negative symptoms on affective ratings in schizophrenia.

Authors:  Anjuli S Bodapati; Ellen S Herbener
Journal:  Psychiatry Res       Date:  2014-04-05       Impact factor: 3.222

10.  Deficit schizophrenia: Concept and validity.

Authors:  Sandeep Grover; Parmanand Kulhara
Journal:  Indian J Psychiatry       Date:  2008-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.